Governance bodies are often described as an oversight and business review function, especially the most senior executive committee. Their meetings become sessions when partners get updates, review progress, and rubber stamp plans that functional subcommittees and...
We’re launching a video series: Partnering on the Edge: The Hard Work of Partnering Well. As part of our deep and long-standing engagement with ASAP, it will be made available to the ASAP community as sponsored content as well as on our YouTube channel and...
September features both an online presentation and the ASAP Summit London. Our focus is on the alliance leader’s evolving mandate to maximize value capture from their alliances. On September 9, we will be leading an online program incorporating roundtable discussions...
Biopharma leaders already understand the industry’s business model has fundamentally shifted. Partnering isn’t an adjunct to internal R&D or a strategic lever pulled selectively. It is the operating model. The work of discovering, developing, and delivering...
Strategic misalignment is not a rare disruption in biopharmaceutical alliances—it is an expected outcome of operating in a dynamic, interdependent industry. It is an inevitability, driven by shifting portfolios, leadership turnover, scientific advances, and external...
Biopharma alliances succeed or fail for reasons that are often misunderstood. Many leaders still assume that partner selection, strategic fit, or agreement quality determine performance. These factors matter, but they do not explain why alliances with similar science,...
Spring conference season is here and The Rhythm of Business is once again pleased to be sponsoring and speaking at two events focused on advancing the profession of alliance management. Jan Twombly will be sharing some of our recent work at two upcoming conferences,...
The biopharma industry’s business model now depends structurally and irreversibly on multi-party execution. Scientific, regulatory, political, and commercial conditions have converged to create unprecedented interdependence. Modalities are more diverse. Clinical...
Alliances have long been a core strategy of biopharmaceutical companies. From early-stage biotech discovery partnerships to global codevelopment and cocommercialization pacts, these collaborations create value for the partners by accelerating drug development,...
In today’s biopharma landscape, complexity is the constant. Portfolios are expanding—not just in size, but in diversity. Collaborations span research to commercialization, startups to multinationals, and molecules to digital platforms. Meanwhile, tightening budgets,...
The biopharmaceutical environment is defined by uncertainty and turbulence. Indiscriminate and sudden cancellation of research grants, workforce contractions, shifting regulatory and policy landscapes, and supply chain instability have become the new reality. Add...
Despite the uncertainty and turbulence defining our economic environment, it has never been more important to partner effectively and realize the intended value of alliances. Based on recent experiences with forward-thinking alliance leaders, a number of core...